A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No
Research payments
$1,630,390
Through program year 2023, $1,630,390 in research payments was reported against A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No, across 469 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $155,243 | 24 |
| 2022 | Research | $182,833 | 46 |
| 2021 | Research | $117,682 | 62 |
| 2020 | Research | $425,976 | 149 |
| 2019 | Research | $748,655 | 188 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Robin Dretler Decatur, GA Named on 16 payments
- Paul Benson Berkley, MI Named on 15 payments
- Moti Ramgopal Port St Lucie, FL Named on 14 payments
- James Sims Bellaire, TX Named on 13 payments
- Gordon Crofoot Houston, TX Named on 12 payments
- Ronald Nahass Somerville, NJ Named on 12 payments
- Joseph Eron Chapel Hill, NC Named on 12 payments
- Roberto Ortiz Orlando, FL Named on 10 payments
- David Prelutsky Saint Louis, MO Named on 9 payments
- Carl Fichtenbaum Cincinnati, OH Named on 9 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.